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Abstract
Introduction—People who continue to smoke after a cancer diagnosis have an increased risk for 
recurrences or development of new malignancies. These risks may be even higher among tobacco-
related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer 
survivors, and people without a history of cancer.
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Methods—We used 2009 Behavioral Risk Factor Surveillance System data to describe 
demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco 
use among TRCS, other cancer survivors, and people without a history of cancer (cigarette 
smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and 
insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, 
esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid 
leukemia.
Results—A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 
%) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other 
cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco 
use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) 
and other cancer survivors (3 %).
Conclusions—The self-reported smoking prevalence among TRCS is higher than among other 
cancer survivors and people without a history of cancer. Targeted smoking prevention and 
cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-
related cancer.
Implications for cancer survivors—We recommend all cancer survivors be made aware of 
the health risks associated with smoking after a cancer diagnosis, and smoking cessation services 
be offered to those who currently smoke.
Condensed abstract—We provide the first population-based report on demographic 
characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.
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Introduction
The cancer survivor population in the United States (US) has grown over the last three 
decades to a projected 13.8 million in 2010 [1–4]. This is largely due to more cancer 
diagnoses as a result of an aging population and improvements in early detection and 
treatment of cancer [5, 6]. Healthy lifestyle behaviors (smoking cessation, physical activity, 
maintaining healthy weight, and consuming a healthy diet) may help improve quality of life 
among cancer survivors and prevent recurrent and subsequent cancers [6].
Smoking is the number one preventable cause of disease and death in the US [7]. A 2004 
Surgeon General Report reviewed the evidence that smoking causes lung, larynx, oral 
cavity, esophagus, and bladder cancers and concluded that it also causes cervix, kidney, 
pancreas, and stomach cancers and acute myeloid leukemia [8]. The annual US incidence of 
tobacco-related cancers is approximately 500,000 [9].
Continued smoking after a cancer diagnosis places survivors at increased risk for 
recurrences or development of new malignancies [10–12]. Nevertheless, the prevalence of 
smoking among cancer survivors is similar to that of the general population [13–18]. 
Although previous studies have examined smoking behaviors among survivors of selected 
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tobacco-related cancers (e.g., lung and cervical) [3, 19–21], none has described smoking 
behaviors among all tobacco-related cancer survivors (TRCS). Furthermore, while 
smokeless tobacco is linked to some cancers (pancreatic, oral, and esophageal) [22–25], 
limited information is available on persistent smokeless tobacco use among cancer survivors 
[13, 26]. We describe tobacco use among persons diagnosed with tobacco-related cancers 
compared with other cancer survivors and people without a history of cancer. Although 
other cancers such as breast and colorectal have also been linked to tobacco use [27, 28], 
this study is limited to tobacco-related cancers identified by the Surgeon General.
Methods
BRFSS survey
The Behavioral Risk Factor Surveillance System (BRFSS) is a state-based system of health 
surveys that collects information on health risk behaviors, preventive health practices, and 
health care access primarily related to chronic disease and injury [29]. The BRFSS is a 
cross-sectional, random-digit–dialed telephone survey of non-institutionalized adults aged 
18 years or older, using trained interviewers and standard core and optional questionnaire 
modules [30]. Data were collected monthly in all 50 states, the District of Columbia, Puerto 
Rico, Guam, and the US Virgin Islands using disproportionate stratified random sampling in 
all states and District of Columbia and simple random sampling in Guam, Puerto Rico, and 
the US Virgin Islands [31]. Approximately 432,607 interviews of adults were completed in 
2009. The median Council of American Survey Research Organizations cooperation rate for 
the 2009 BRFSS was 75 %, and the response rate was 53 % [32].
In the 2009 BRFSS survey, questions about cancer survivorship were included on the core 
module and thus were administered by all states, District of Columbia, and territories. 
Respondents were asked if they had ever been told by a doctor, nurse, or other health care 
professional that they had cancer. If they answered yes, they were asked how many different 
types of cancer they had had, their age at first diagnosis, and the type of cancer. If 
respondents reported more than one cancer, the most recent was recorded and included in 
this study. Respondents who had an unknown history of cancer, who refused to answer the 
question, or who reported non-melanoma skin cancer were excluded from the analysis. 
Basal and squamous cell skin cancers typically do not require treatment beyond surgery and 
are not routinely collected in cancer registries [1].
We assessed demographic characteristics and tobacco use among TRCS, other cancer 
survivors and respondents without cancer. Respondents who reported a cervical, oral, 
pharyngeal, esophageal, pancreatic, leukemia, stomach, lung, bladder, or renal (kidney) 
cancer diagnosis were included in the TRCS population. Respondents who reported a prior 
cancer diagnosis at any other site (including “other”) were included in the population of 
other cancer survivors. The tobacco-related cancers acute myelogenous leukemia and 
laryngeal cancer were not included in the 2009 BRFSS questionnaire. BRFSS does not 
specify types of leukemia; therefore, all types are combined into one response. Acute 
myelogenous leukemia is the second most commonly diagnosed leukemia in the US [33]. To 
capture acute myelogenous leukemia survivors, all patients who reported a leukemia 
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diagnosis were included in the TRCS population. Laryngeal cancer survivors were listed as 
“other” in the BRFSS survey and therefore not included in the TRCS analyses.
We report the following demographic characteristics: sex, age, age at first cancer diagnosis, 
years since first diagnosis, race, ethnicity, education level, health insurance status, and US 
census region of residence. We calculated years since diagnosis using the respondents’ 
current age and age at first cancer diagnosis. Respondents were asked the following 
question: Would you say that in general your health is—excellent, very good, good, fair, or 
poor?” As a proxy for general health status, we compared the proportion of respondents who 
indicated “poor health.” To determine cigarette smoking status, respondents were asked, 
“Have you smoked at least 100 cigarettes in your entire life?” Those who answered yes were 
classified as “current smokers” if they smoked at the time of the interview and “former 
smokers” if they did not. Current smokeless tobacco use was defined as an answer of “every 
day” or “some days” to the following question: “Do you currently use chewing tobacco, 
snuff, or snus [a small pouch of smokeless tobacco] every day, some days, or not at all?” To 
measure cigarette smoking cessation, quit ratios (also termed quit rates) were calculated by 
dividing the number of former smokers by the number of ever smokers (current+former) 
[34].
We compared demographic characteristics and tobacco use reported by respondents without 
cancer, TRCS, and other cancer survivors. Current smoking prevalence was also stratified 
by sex, age, race, years since diagnosis, and cancer site. For some analyses (indicated as 
“adjusted”), we used logistic regression to produce adjusted percentages (i.e., predicted 
marginals [65]), which is a method of standardization that produces a weighted average for 
each level of the health variable of interest. This method allows for comparison between 
cancer survivors and individuals with no cancer history as if both groups had the same 
demographic characteristics. Separate models were fit with each health variable as the 
dependent variable while controlling for age, race/ethnicity, sex, employment status, 
insurance coverage, and cancer status as independent variables. We used multinomial 
logistic regression if the categorical dependent variable of interest had more than two levels. 
Separate logistic regression models were run for each time period since diagnosis to estimate 
the smoking prevalence among cancer survivors ≤5, 6–10, and >10 years since diagnosis. 
Unadjusted smoking prevalence was used for analyses in which we stratified data by 
demographics included in the adjusted model (age, sex, race, and insurance status); 
otherwise, adjusted smoking prevalence data are presented.
We used SAS (SAS Institute, Cary, NC) version 9.2 and SAS-callable SUDAAN release 10 
(Research Triangle Institute, Research Triangle Park, NC) to account for the complex 
sampling design of the BRFSS and to provide population estimates. Weights were applied to 
calculate respondents’ probability of being selected for the survey in their respective state or 
territory and adjusted to race/ethnicity-, age-, and sex-specific population numbers from 
current census data (or intercensal estimates). We present weighted self-reported prevalence 
estimates, along with 95 % confidence intervals to indicate statistical significance. P values 
were calculated from Rao Scott chi-square test or linear contrasts between populations.
Underwood et al. Page 4















Eight percent of all BRFSS respondents reported previously being diagnosed with cancer 
(Table 1). Among cancer survivors, 20 % were TRCS. Women accounted for a majority of 
respondents without cancer (51 %), TRCS (68 %), and other cancer survivors (58 %). The 
mean age of TRCS was 57 years, compared with 63 years for other cancer survivors and 45 
years for respondents without cancer.
Among cancer survivors (Table 1), TRCS were younger when diagnosed with cancer (mean 
age=45 years) compared with other cancer survivors (53 years), and a larger proportion of 
TRCS had been diagnosed more than 10 years ago (45 %) compared with other cancer 
survivors (38 %). Nonwhite respondents accounted for 22 % of TRCS and 19 % of other 
cancer survivors. A larger proportion of TRCS reported poor general health status (16 %), 
when compared with other cancer survivors (10 %) and respondents without cancer (4 %). 
TRCS were less educated compared with other cancer survivors; only 26 % of TRCS were 
college graduates, compared with 36 % of other cancer survivors. A total of 11 % of TRCS 
were uninsured, compared with 6 % of other cancer survivors. Cervical cancer was the most 
commonly reported among TRCS, followed by lung, bladder, and renal cancer (Table 2).
Tobacco use
The adjusted current smoking prevalence was 27 % among TRCS compared with 16 % 
among other cancer survivors and 18 % among respondents without cancer (Table 3). The 
adjusted smokeless tobacco prevalence was higher among respondents without cancer (4 %) 
compared with TRCS (3 %) and other cancer survivors (3 %). One third of TRCS were 
former smokers, compared with 26 % of other cancer survivors and 24 % of respondents 
without cancer. The smoking quit ratio was highest among other cancer survivors (62 %), 
followed by respondents without cancer (57 %) and TRCS (55 %).
The unadjusted smoking prevalence was higher among men (20 %) than women (16 %) 
among respondents without cancer, but was higher among women than men for TRCS (31 
% vs. 18 %) and other cancer survivors (12 % vs.10 %) (Fig. 1). Smoking prevalence 
decreased with older age in all 3 groups studied (Fig. 2). When stratified by time since 
diagnosis, adjusted smoking prevalence slightly increased among TRCS and other cancer 
survivors by comparing those recently diagnosed with cancer (<5 years) to long-term cancer 
survivors (10<years) (Fig. 3). Nearly half of all American Indian/Alaska Native (AI/AN) 
and multiracial TRCS were current smokers (Fig. 4). Smoking prevalence in all racial/ethnic 
groups was higher among TRCS when compared with other cancer survivors and 
respondents without cancer (Fig. 4). When examined by selected cancer sites, adjusted 
smoking prevalence was significantly higher among cervical cancer survivors (32.9 %) 
compared with bladder (27.3 %), lung (23.5 %), and renal (23.2 %) cancer survivors (Fig. 
5).
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We found a high prevalence of cigarette smoking among TRCS, despite the well-
documented health risks of smoking after a cancer diagnosis [10, 35]. Smoking prevalence 
was significantly higher among TRCS, compared with other cancer survivors and highest 
among younger survivors.
Cigarette smoking is especially harmful for people previously diagnosed with cancer [10]. 
Cancer survivors who continue to smoke are less likely to respond to treatment [36], 
experience exacerbated toxicity due to chemotherapy [37], and have lower survival rates 
than patients who stopped smoking before or at time of diagnosis [19, 38]. Despite these 
risks, studies have shown persistent smoking among cancer survivors. Smoking rates among 
childhood [13], adolescent [15], and adult cancer survivors [17] are similar to the smoking 
prevalence in the general population. One study reported a higher smoking prevalence in 
cancer survivors in Massachusetts compared with the general population [18]. Similar to 
prior reports [39], the smoking prevalence in our non-cancer population was highest among 
men. In the two groups of cancer survivors, however, rates were higher among women. A 
prior report using data from the National Health Interview Survey showed high smoking 
rates among selected subgroups of cancer survivors, including young cancer survivors (<40 
years) [3], This is consistent with our finding of the highest smoking prevalence among 
young persons diagnosed with cancer.
Time since cancer diagnosis also influences smoking prevalence among cancer survivors. 
Smoking prevalence initially declines after a cancer diagnosis, but eventually re-emerges 
among longer-term survivors (>20 years) [40]. Similarly, we found that the smoking 
prevalence among TRCS increased with time since diagnosis, although we did not observe 
an initial decline in the first years post diagnosis. Smoking prevalence among other cancer 
survivors also slightly increased among long-term survivors.
Compared with other cancer survivors, a larger proportion of TRCS was younger than 40 
years, AI/AN, multiracial, less educated, and uninsured. According to previous findings on 
smoking prevalence among the US population, the same demographics are associated with 
high smoking prevalence [41]. Smoking is highest among young people and declines with 
increasing age [42]. Compared with other cancer survivors, the TRCS population in this 
study had a larger proportion of younger people, which may have contributed to a higher 
smoking prevalence. The larger proportion of multiracial and AI/AN respondents may also 
contribute to the higher smoking prevalence among TRCS because these groups have a high 
smoking prevalence compared with other racial/ethnic groups [39]. Finally, the higher 
smoking prevalence among TRCS (compared with other cancer survivors) may also be 
driven by poor and less educated populations, which have significantly higher smoking rates 
in the general population [39]. Socio-economic factors such as less education and lower 
household income may have influenced our findings, as they have been linked with high 
smoking rates, specifically among cancer survivors [66]. Though we attempted to control for 
SES by adjusting for insurance status when calculating smoking prevalence among the 
different populations, we were unable to provide a detailed description of SES in this study.
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Cancer survivors have an increased risk for second primaries (subsequent cancers), 
osteoporosis, obesity, cardiovascular disease, diabetes, and other comorbidities [67]. A 
recent publication on cancer survivorship found that a substantial proportion of cancer 
survivors also suffer from heart disease, diabetes, asthma, and other health-related illness 
[68]. Persons with co-morbidities are typically older and have more interaction with health 
care providers, therefore more opportunity for counseling to quit smoking. Thus, the lower 
smoking prevalence among the older non-TRCS population may be associated with co-
morbidities.
While studies have shown that approximately 15–20 % of lung, larynx, and pharynx 
survivors continue to smoke after cancer diagnosis [40, 69]; we currently have limited 
information on the smoking prevalence of many TRCS. This is not the case for cervical 
cancer survivors, who have a well-documented, high persistent smoking prevalence [3, 71]. 
In fact, the high smoking prevalence among the TRCS population in our study was largely 
due to smoking among cervical cancer survivors. Cervical cancer is typically diagnosed in 
younger women and treated successfully [43]; therefore, cervical cancer survivors account 
for a large proportion of TRCS—44 % in this study—and they report a smoking prevalence 
of nearly 35 %. Prior studies also report high rates of smoking among cervical cancer 
survivors and subsequently an increased risk for future cancer diagnoses [3, 44, 45]. A 
recent CDC report found cervical cancer survivors have an increased risk for other 
subsequent tobacco-related cancers when compared with persons never diagnosed with 
cancer and other cancer survivors [70]. Among cervical cancer survivors, those who 
continue to smoke after diagnosis are 21 % more likely to die from cervical cancer 
compared with those who do not smoke [46]. Much like smoking prevalence [47–49], 
cervical cancer is most common in poor and underserved women [50, 51] and those who 
reside in rural areas [52]. Because of the high smoking prevalence among cervical cancer 
survivors and the potential effect of socioeconomic status on access to quality care, smoking 
prevention and cessation services should be prioritized for this high-risk population.
Tobacco cessation treatments are effective among smokers with various medical conditions, 
including cancer [53]. We found differences in smoking cessation prevalence (quit ratios) 
among cancer survivors; the prevalence of ever smokers who have quit was 7 % higher 
among other cancer survivors compared with TRCS. Our assessment of general health status 
revealed TRCS reported poorer health than other cancer survivors. This may result in more 
interaction with health care providers, providing opportunity for intervention with evidence-
based smoking cessation treatment. Therefore, we recommend targeting TRCS with 
effective, evidence-based tobacco cessation strategies, such as counseling by a health care 
provider and pharmacotherapy [54]. A recent study reported that the smoking status among 
one in four cancer survivors who currently smoke is not known by a health care provider 
and that only 72 % of cancer survivors who currently smoke were advised to quit smoking 
by a health care provider [55]. These findings reveal missed opportunities for health care 
providers to advise cancer survivors against smoking and provide evidence-based 
interventions. A separate report found that despite the importance of tobacco use cessation 
counseling for all cancer patients, the diagnosis of cancer may be underused as a teachable 
moment [54].
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To our knowledge, this is the first population-based study to examine smokeless tobacco use 
among TRCS. Approximately 3 % of cancer survivors (TRCS and other cancer survivors) in 
this study used smokeless tobacco products. Previous cohort studies have shown the 
prevalence of use ranges from 1–6 % [56, 57]. The same studies also report smokeless 
tobacco use was significantly higher among males. Our comparably low prevalence of 
smokeless tobacco use may be partly because fewer males were among cancer survivors in 
this report. Current smokers who are attempting to quit may substitute cigarettes for 
smokeless tobacco products [58]; however, we were unable to determine if our respondents 
did so. A global evaluation by the International Agency for Research on Cancer linked oral 
cancers to the use of smokeless tobacco products in several studies [59]. Further studies on 
smokeless tobacco use and smoking cessation among cancer survivors are warranted.
Our findings are subject to several limitations. First, BRFSS data are self-reported and 
subject to recall bias and misclassification, which could lead to inaccurate estimates of 
cancer prevalence [60]. Recall bias may be responsible for the slightly higher cancer 
prevalence we observed of certain cancers, compared with a recent study using cancer 
registry data [1]. Over-reporting of cervical cancer may have occurred in this study because 
some women may misunderstand abnormal Pap smears, cervical cancer precursors, and 
cervical intraepithelial neoplasia to be cancer because of treatments used to remove the 
precancerous lesions [61]. Some of the tobacco-related cancers defined by the Surgeon 
General (acute myelogenous leukemia and laryngeal cancer) were not specifically queried in 
the BRFSS survey. To capture acute myelogenous leukemia survivors, we included all 
patients who reported a leukemia diagnosis in tobacco-related analyses, thereby possibly 
overestimating the TRCS population. Laryngeal cancer survivors would have likely 
indicated “other” cancer type and been included in the analyses of other cancer survivors. 
Second, the survey may not be representative of people who do not have a landline 
telephone, which is required for BRFSS participation [62]. Households with landline 
telephone are associated with higher educational attainment [62]. Third, because our 
findings are limited to non-institutionalized US citizens, we did not assess cancer survivors 
who may have advanced disease and are living in nursing homes, long-term care facilities, 
or hospice. Fourth, this survey does not collect information from people younger than 18 
years; thus, we are unable to describe the characteristics and health behaviors of this 
population. Fifth, BRFSS does not assess any indicators of smoking dependence or intensity. 
Therefore, we are unable to draw conclusions on the magnitude of tobacco use among 
cancer survivors. Finally, low cooperation for the BRFSS survey may limit the 
generalizability of our study findings to all cancer survivors living in the US. However, 
studies have concluded that the national survey findings are reliable and valid [63], 
providing a major strength to this study.
Too many cancer survivors continue to smoke despite evidence that doing so places them at 
increased risk for a new or recurrent cancer diagnosis [10]. Continued smoking after a 
cancer diagnosis can also increase toxicity due to chemotherapy, delay healing after surgery, 
impede patient recovery to daily functioning, and decrease a patient’s chance for survival 
[54], We recommend that smoking cessation services be offered to all cancer survivors. 
Public health practitioners should implement programs that promote effective tobacco 
cessation and prevention practices for cancer survivors, such as patient education, cessation 
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counseling, pharmacotherapy (e.g., nicotine replacement and antidepressants), and any 
combination of proven practices [54]. One such program for cancer survivors provided peer 
counseling, tailored educational materials, and free pharmacotherapy, resulting in a 
significantly higher smoking quit rate among program participants compared with those 
assigned to a self-help group [64]. Patient education about the risks associated with smoking 
after a cancer diagnosis is also warranted to decrease smoking among cancer survivors. 
Finally, we recommend that health care professionals continue to advise cancer survivors 
against smoking and offer evidence-based tobacco cessation options to patients who are 
smokers.
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Unadjusted smoking prevalence by sex among TRCS, other cancer survivors, and 
respondents without cancer [32]. BRFSS Behavioral Risk Factor Surveillance System. All 
data are based on self-report and are weighted. For cancer survivors reporting more than one 
cancer diagnosis, the cancer site reported was the most recently diagnosed cancer. TRCS 
include respondents who report a prior diagnosis of lung/bronchial, pharyngeal, esophageal, 
stomach, pancreatic, kidney/renal, urinary bladder, or cervical cancer. Tobacco-related 
cancers are defined according to a 2004 Surgeon General report [8]. To capture acute 
myelogenous leukemia survivors, all patients who reported a leukemia diagnosis were 
included in the tobacco-related cancer survivor population. Other cancer survivors include 
respondents who report a prior diagnosis of any cancer, not designated as tobacco related. 
Respondents without cancer include anyone who reports never being diagnosed with cancer. 
Current smoking defined as regular or intermittent smoking and having smoked >100 
cigarettes ever. *p<0.05; p values calculated from Rao Scott chi-square test
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Unadjusted smoking prevalence by age among TRCS, other cancer survivors, and 
respondents without cancer [32]. BRFSS Behavioral Risk Factor Surveillance System. All 
data are based on self-report and are weighted. For cancer survivors reporting more than one 
cancer diagnosis, the cancer site reported was the most recently diagnosed cancer. TRCS 
include respondents who report a prior diagnosis of lung/bronchial, pharyngeal, esophageal, 
stomach, pancreatic, kidney/renal, urinary bladder, or cervical cancer. Tobacco-related 
cancers are defined according to a 2004 Surgeon General report [8]. To capture acute 
myelogenous leukemia survivors, all patients who reported a leukemia diagnosis were 
included in the tobacco-related cancer survivor population. Other cancer survivors include 
respondents who report a prior diagnosis of any cancer not designated as tobacco related. 
Respondents without cancer include anyone who reports never being diagnosed with cancer. 
Current smoking defined as regular or intermittent smoking and having smoked >100 
cigarettes ever. *p<.05; p values calculated from Rao Scott chi-square test
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Adjusted smoking prevalence by time since diagnosis among TRCS and other cancer 
survivors [32]. BRFSS Behavioral Risk Factor Surveillance System. All data are based on 
self-report and are weighted. For cancer survivors reporting more than one cancer diagnosis, 
the cancer site reported was the most recently diagnosed cancer. TRCS include respondents 
who report a prior diagnosis of lung/bronchial, pharyngeal, esophageal, stomach, pancreatic, 
kidney/renal, urinary bladder, or cervical cancer. Tobacco-related cancers are defined 
according to a 2004 Surgeon General report [8]. To capture acute myelogenous leukemia 
survivors, all patients who reported a leukemia diagnosis were included in the tobacco-
related cancer survivor population. Other cancer survivors include respondents who report a 
prior diagnosis of any cancer, not designated as tobacco-related. Current smoking defined as 
regular or intermittent smoking and having smoked >100 cigarettes ever. Smoking 
prevalence adjusted for race/ethnicity, sex, age, insurance coverage, and employment status
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Unadjusted smoking prevalence by race and ethnicity among TRCS, other cancer survivors, 
and respondents without cancer [32]. BRFSS Behavioral Risk Factor Surveillance System, 
NH Native Hawaiian, PI Pacific Islander, AI/AN American Indian/Alaska native. All data 
are based on self-report and are weighted. For cancer survivors reporting more than one 
cancer diagnosis, the cancer site reported was the most recently diagnosed cancer. TRCS 
include respondents who report a prior diagnosis of lung/bronchial, pharyngeal, esophageal, 
stomach, pancreatic, kidney/renal, urinary bladder, or cervical cancer. Tobacco-related 
cancers are defined according to a 2004 Surgeon General report [8]. To capture acute 
myelogenous leukemia survivors, all patients who reported a leukemia diagnosis were 
included in the tobacco-related cancer survivor population. Other cancer survivors include 
respondents who report a prior diagnosis of any cancer, not designated as tobacco-related. 
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Respondents without cancer include anyone who reports never being diagnosed with cancer. 
Current smoking defined as regular or intermittent smoking and having smoked >100 
cigarettes ever
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Adjusted smoking prevalence by site among TRCS [32]. BRFSS Behavioral Risk Factor 
Surveillance System. All data are based on self-report and are weighted. For cancer 
survivors reporting more than one cancer diagnosis, the cancer site reported was the most 
recently diagnosed cancer. TRCS include respondents who report a prior diagnosis of lung/
bronchial, pharyngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, or 
cervical cancer. Tobacco-related cancers are defined according to a 2004 Surgeon General 
report [8]. To capture acute myelogenous leukemia survivors, all patients who reported a 
leukemia diagnosis were included in the tobacco-related cancer survivor population. Data 
for pharyngeal, esophageal, stomach, pancreatic, urinary, and leukemia cancer sites were 
suppressed because of sample size of <50 or half width of CI of >10. Current smoking 
defined as regular or intermittent smoking and having smoked >100 cigarettes ever. 
Smoking prevalence adjusted for race/ethnicity, sex, age, insurance coverage, and 
employment status. *p<.05; p values calculated from linear contrasts between cervical and 
other cancer sites
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Table 2
Distribution of self-reported cancer survivors by site[32]
Cancer type Number Percentage 95 % CI
TRCSa
Cervical 1,398,474 44.2 42.2–46.3
Head/neck 106,612 3.4 2.7–4.1
Oral 83,167 2.6 1.9–3.4
Pharyngeal 96,759 3.1 2.4–3.7
Esophageal 47,296 1.5 1.1–1.9
Pancreatic 61,153 1.9 1.4–2.5
Stomach 73,788 2.3 1.8–2.9
Leukemia 237,209 7.5 6.4–8.6
Lung 445,055 14.1 12.4–15.8
Bladder 367,569 11.6 10.5–12.7
Renal 244,826 7.7 6.7–8.8
Other cancer survivorsb
Breast cancer 3,135,383 24.7 23.9–25.5
Endometrial cancer (cancer of the uterus) 519,140 4.1 3.7–4.5
Ovarian cancer (cancer of the ovary) 467,568 3.7 3.3–4.1
Thyroid 429,033 3.4 3.0–3.7
Colon 1,000,723 7.9 7.4–8.4
Liver 66,426 0.5 0.4–0.7
Rectal 76,851 0.6 0.5–0.7
Hodgkin’s lymphoma 276,828 2.2 1.9–2.5
Non-Hodgkin’s lymphoma 309,034 2.4 2.0–2.9
Prostate 2,155,621 17.0 16.2–17.7
Testicular 185,258 1.5 1.1–1.8
Melanoma 1,971,310 15.5 14.9–16.2
Heartc – – –
Bone 110,416 0.9 0.6–1.1
Brain 93,969 0.7 0.5–0.9
Neuroblastomac – – –
Otherd 1,434,360 11.3 10.6–12.0
All data are based on self-report and are weighted. For cancer survivors reporting more than one cancer diagnosis, the cancer site reported was the 
most recently diagnosed cancer
BRFSS Behavioral Risk Factor Surveillance System, TRCS tobacco-related cancer survivors
a
Include respondents who report a prior diagnosis of lung/bronchial, pharyngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, or 
cervical cancer. Tobacco-related cancers are defined according to a 2004 Surgeon General report [8]. To capture acute myelogenous leukemia 
survivors, all patients who reported a leukemia diagnosis were included in the tobacco-related cancer survivor population
b
Include respondents who report a prior diagnosis of any cancer not designated as tobacco-related
c
Data for heart and neuroblastoma cancer sites were suppressed because of sample size of <50 or half width of CI of >10
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d
Other cancer sites include brain, bone, thyroid, heart and the response category of other; laryngeal cancer (a tobacco-related cancer) was not 
included in the 2009 BRFSS survey and is therefore included as “other” cancer
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